中等剂量卡培他滨单药治疗老年转移性乳腺癌临床探讨

Clinical Observation of Median Dose of Capecitabine in Treatment of Elderly Patients with Metastatic Breast Cancer

目的探讨中等剂量卡培他滨单药治疗老年转移性乳腺癌的治疗效果及不良反应。方法整群选择2012年3月—2014年2月来该院治疗老年转移性乳腺癌的患者76例,随机分成两组,每组38例,对照组患者采用大剂量卡培他滨,治疗组患者采用中等剂量卡培他滨。观察两组患者治疗效果及不良反应。结果治疗组与对照组患者的治疗总有效率和肿瘤控制率相比差异无统计学意义(P>0.05);治疗组患者的不良反应明显少于对照组患者,差异有统计学意义(P<0.05)。结论中等剂量卡培他滨单药治疗老年转移性乳腺癌的效果较好,且不良反应较小,值得临床推广。

Objective To observe the treatment effect and toxic and side effect of moderate dose of capecitabine in treatment of elderly patients with metastatic breast cancer. Methods 76 cases of elderly patients with metastatic breast cancer treated in our hospital from March 2012 to February 2014 were selected and randomly divided into control group and treatment group with 38 cases in each, the control group were given large dose of capecitabine, the treatment group were given median dose of capecitabine, the treatment effects and toxic and side effects of the two groups were observed. Results There was no obvious difference in the total effective rate and tumor control rate between the treatment group and the control group（P〉0.05）; toxic and side effects in the treatment group were obviously fewer than those in the control group, and the difference was significant（P〈0.05）. Conclusion Median dose of capecitabine in treatment of elderly patients with metastatic breast cancer has a better effect and a smaller toxic and side effect, which is worth promoting in clinic.